ANZUP trials - bladder
ANZUP are currently running a number of bladder cancer trials. For more details information about these trials, go to the ANZUP bladder cancer trials web page: http://bit.ly/ANZUPbladder
BCG+MM Status: Open & recruiting Location: Australia Activated sites: 12 Patients recruited: 309 Patients required: Stage one: 130 / Stage two: 370
Non-muscle invasive bladder cancer is common and causes substantial suffering. It requires removal or irradiation of the bladder within five years in more than 30% of people with high-risk tumours, despite best current treatment. Recent preliminary studies show promising results from adding mitomycin (MM), a chemotherapy drug, to current treatment with BCG (Bacillus Calmette-Guérin, a strain of modified bacteria which stimulates an immune response to early cancer cells). This randomised trial will determine the effects of adding mitomycin on cure rates, survival, side effects and quality of life. This could potentially provide a simple and costeffective treatment for patients who suffer from this cancer. This study is currently active and recruiting. Please speak with your doctor if this is of interest to you or someone you know. ANZUP collaborates with the University of Sydney through the National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC).
This ANZUP investigator-initiated study is being funded by Cancer Australia and the National Health and Medical Research Council. We acknowledge Omegapharm and Merck Sharp & Dohme for providing the study drugs. Current site locations for the BCG + MM trial are: NSW • Concord Repatriation General Hospital • John Hunter Hospital • Northern Cancer Institute, St Leonards • Southside Cancer Care Centre • The Tweed Hospital • Westmead Hospital VIC • The Alfred Hospital • Austin Hospital • Epworth HealthCare (Richmond) • Frankston Hospital • Royal Melbourne Hospital WA • Fiona Stanley Hospital
A LITTLE BELOW THE BELT 37
